Oncology Biosimilars Market Growth Through 2030 Creates New Strategic Opportunities
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Oncology Biosimilars Market Size Outlook: How Fast Will Revenue Grow Through 2030?
The oncology biosimilars market has experienced swift expansion in recent years. Its value is projected to rise from $11.35 billion in 2025 to $12.83 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.0%. Historical growth has been driven by factors such as the elevated cost of reference biologics, a constrained supply of oncology biosimilars, a rising worldwide incidence of cancer, an expanding hospital and pharmacy infrastructure, and the early approval of monoclonal antibody biosimilars from regulatory authorities.
The oncology biosimilars market is poised for significant expansion in the upcoming years, with projections indicating it will reach $21.28 billion by 2030, driven by a compound annual growth rate (CAGR) of 13.5%. This anticipated growth during the forecast period is fueled by the introduction of novel biosimilar drugs such as pembrolizumab and pegfilgrastim, the broadening of online pharmacy distribution networks, a heightened uptake of immunomodulators and hematopoietic agents, increased governmental efforts to enhance cancer care accessibility, and a stronger emphasis on individualized oncology therapies. Key developments shaping this period include the growing popularity of biosimilars for rituximab, trastuzumab, and bevacizumab, a rising application of immunomodulators and hematopoietic agents in cancer treatment, the expansion of G-CSF biosimilars for managing neutropenia, the widening presence of hospital and retail pharmacy channels dedicated to oncology biosimilars, and a concentrated push toward affordable and accessible cancer treatment solutions.
Download A Free Sample Report For Comprehensive Market Insights:
Oncology Biosimilars Market Growth Drivers: What Factors Are Accelerating Expansion?
The expiration of patents on biologics used in cancer treatment is fueling the development of new oncology biosimilars. Since biologics are protected by patents for only a finite duration, their expiry opens the door for producing biosimilars. These biologics are targeted therapies created from living organisms, designed to stimulate the immune system to combat cancer cells. Biosimilars, while not identical to their biologic counterparts, deliver comparable effectiveness at a lower cost. For example, as reported by DrugTimes, a Chinese firm specializing in pharmaceuticals and biotechnology, in February 2024, over 25 drugs are projected to lose patent protection by 2037, which could lead to a combined revenue drop exceeding $236.4 billion based on 2024 sales. This growing number of patent expirations is anticipated to boost the demand for manufacturing new oncology biosimilars, thereby propelling the growth of the oncology biosimilars market.
Oncology Biosimilars Market Segment Performance And Strategic Opportunities
The oncology biosimilars market covered in this report is segmented –
1) By Drug Type: Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)
2) By Cancer Type: Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types
3) By Distribution Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Monoclonal Antibody: Rituximab Biosimilars, Trastuzumab Biosimilars, Bevacizumab Biosimilars, Pembrolizumab Biosimilars
2) By Immunomodulators: Thalidomide Biosimilars, Lenalidomide Biosimilars, Pomalidomide Biosimilars
3) By Hematopoietic Agents: Epoetin Biosimilars, Darbepoetin Biosimilars
4) By Granulocyte Colony-Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars
Oncology Biosimilars Market Trends: What Is Shaping Future Industry Growth?
Leading corporations within the oncology biosimilars sector are directing their efforts toward the creation of cutting-edge cancer therapies—including targeted biologics and monoclonal antibodies—aimed at improving treatment effectiveness, patient recovery, and the overall availability of oncology services. Monoclonal antibodies (mAbs) represent lab-crafted proteins engineered to identify and attach to specific antigens present on cancer cells, which facilitates accurate targeting and immune-driven elimination. A notable example occurred in March 2023, when Pfizer, an American pharmaceutical firm, finalized a merger with Seagen involving a $43 billion investment to bolster its oncology pipeline. This strategic acquisition strengthens Pfizer’s position in cancer treatment development and promotes progress in advanced therapies that combat cancer, a prevalent global cause of mortality. This investment additionally highlights a rising pattern of substantial financial commitments dedicated to novel oncology biosimilars, designed to fulfill unmet healthcare requirements and broaden access to cancer care on a worldwide scale.
Oncology Biosimilars Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the oncology biosimilars market are Biocon Biologics Limited, Celltrion Inc., Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen Inc., F. Hoffmann-La Roche, Sanofi SA, Mylan, Samsung Bioepis, Biogen International GmbH, Merck & Co. Inc., Coherus Biosciences, Eli Lilly and Company, Novartis AG, Viatris Inc., Accord Healthcare Ltd., Zydus Cadila Health Care Limited, Hetero Drugs Limited, Mundipharma International Limited, Mabion SA, Polpharma Biologics, Alvotech, Innovent Biologics, Gan & Lee Pharmaceuticals, Henlius Biotech
Access The Complete Oncology Biosimilars Market Report:
Oncology Biosimilars Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the global oncology biosimilars market in 2025. Middle East is expected to be the fastest-growing region in the oncology biosimilars market report forecast period. The regions covered in the oncology biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
